Company's patented multi-target therapeutics® platform establishes a new class of patient-friendly treatmentsANNAPOLIS, Md., ...

DURHAM, N.C., March 17, 2026 - MedPharm, a global leader in topical and transdermal contract drug development and ...

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat adults with moderate-to-severe bullous pemphigoid: Paris Wednesday, March 25, 2026, 09:00 Hrs [IST] T ...

This next in a series of quick quizzes in dermatology asks -what’s the cause of this itchy, vesicular rash on the hands?

The U.S. Food and Drug Administration has approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients with a ...

Cerebral folate deficiency is a rare neurological disorder characterized by a decrease in CSF folate levels, leading to developmental regression, seizures, movement disorders, and other neurological ...

Drug's approval expanded, but only to patients with genetic cerebral folate transport defi ...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained ...

The FDA approved leucovorin for cerebral folate deficiency linked to FOLR1 mutations but said evidence is insufficient to support approval for autism.

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of ...

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.